Nano Technology To Measure Blood Glucose Levels

Nano Technology To Measure Blood Glucose Levels

Diabetech says preliminary results from our GlucoPals Study proving that patient-centric real-time communication facilitates tighter glucose control. Other findings include improved insulin dosing accuracy, better family relationships, peace of mind for the family, and more frequent blood glucose testing.
Due to the overwhelming evidence and patient feedback, Diabetech is immediately stepping up its marketing efforts around this medically necessary and covered diabetes management technology. Based on the preliminary GlucoPals subscriber data, Diabetech is now expanding its guarantee to include tighter glucose control or the service is free.

Recommended for families with diabetic children ages 8 and up, the interactive wireless communication system connects the child directly with his/her parents, school personnel, and any number of GlucoPALS (diabetes pen-pals) no matter where they live as well as providing the team with direct access to the patient in real-time.

Meanwhile Zyvex Corporation, a leading molecular nanotechnology company specializing in micro and nanomanufacturing, micro electro mechanical systems (MEMS), and nanomaterials has selected Diabetech, LP as its medical device development and commercialisation partner for their wireless sensor implant targeting real-time blood glucose levels in the body.

Diabetech provides the know-how and patented technologies necessary to develop the innovative patients handheld device for not only displaying the glucose levels from the implant to the patient but also for automatically relaying that information in real-time to Diabetechs clinical management system. Diabetech will also be responsible for commercializing this leading-edge medical device technology as part of its Virtual-Loop Program.

What a great use for this technology!

German researchers design hybrid bio-synthetic nanoparticles to fight cancer

German researchers design hybrid bio-synthetic nanoparticles to fight cancer
They are only a few nanometers in size, but their impact is tremendous: The tiny particles drive cancer cells to their death in no time at all. At nano tech 2006 in Japan from Feb. 21-23 researchers from the German Fraunhofer-Gesellschaft will demonstrate in Hall 4 the great efficiency of nanoscopic particles as a vehicle for drug delivery.

Medicines that will make their own way through the body and attack precisely the diseased cells on reaching their destination such has been the dream of physicians and pharmacists since time immemorial. Fraunhofer researchers working in the Fraunhofer Nanotechnology Alliance have now come a little closer to reaching this goal. They have developed bio-functional nanoparticles that cause necrosis in cancer cells. “These cell-like structures have a solid nucleus surrounded by proteins that detect and destroy cancer cells,” explains Dr. Tovar of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB.

So how does it work? “Communication in the human body is a biochemical process based on the exchange of molecules,” says Tovar. “We are trying to understand these communication processes and harness them for our own purposes.” The tumor necrosis factor TNF for instance, releases a molecule that attaches itself to the receptors of the cancer cell and passes on its deadly message. To introduce the biological messenger TNF into the body, Tovar and his colleagues at Stuttgart University have developed bio-functional nanoparticles. Known as nanocytes, these carry TNF proteins on their surface. “In producing these particles, we benefit from the self-organizing capability of the ‘building blocks’: Once a contact has been established between the particles and the proteins, the proteins grow and envelop the nuclei without any further effort on our part,” the researcher explains. Tovar tested the finished nanoparticles in a Petri dish. His findings were most encouraging: cancer cells that came into contact with the particles did indeed perish. The researchers documented this process on video, and will be showing the film at the Fraunhofer stand at nano tech 2006.

Water Fuel

A group of Malaysian scientists who developed the V1 hydrogen fuel technology (HFT), which can significantly reduce fuel consumption and cost, hopes to work with companies to commercialise it.

Its spokesman Mohammad Isa Abdullah said a prototype had been developed and RM5mil was needed for the system to be commercialised.

We have yet to identify the companies which we can work with, but there has been some interest, he told Bernama.

We believe that the project is not only viable but is also of great national interest. The successful launch of the project will result in a substantial reduction in fuel costs for car users and subsidy costs incurred by the Government, he said.

He added that with further research and development, the project could pave the way for groundbreaking innovations to create opportunities in Malaysia.

HFT is designed to fit any car with emphasis on national cars like the Perdana, Waja, Wira, Iswara, Saga and Kancil. The technology uses water as a complementary fuel to petrol and diesel.

It is based on high compression nano-technology that breaks down water into hydrogen and oxygen, that are then pumped into the fuel line.

The new fuel mixture, petrol/diesel (hydrogen and oxygen), is injected into the engine where combustion takes place.

The prototype has been used in a Proton Waja which has clocked 10,000km.

The fuel H2O is able to generate a fuel capacity of 20 litres (10 from petrol and 10 from H2O). For every 10 litres of petrol, the system uses 20 litres of H2O to generate a fuel capacity of 20 litres.

UCLA develops nanotechnology safety test

UCLA develops nanotechnology safety test

UCLA scientists have developed a testing strategy to help manufacturers monitor and test the safety and health risks of engineered nanomaterials.

Nanotechnology involves manipulating atoms to create molecules smaller than one one-thousandth the diameter of a human hair. “Nano” means one billionth of a meter and the field might exceed the impact of the Industrial Revolution, becoming a $1 trillion market by 2015.

No government or industry regulations yet exist for the emerging technology.

At such small sizes, materials exhibit unconventional physical and chemical properties that allow them to perform new feats in the areas of electronics, optics, and drug delivery.

Engineered nanomaterials are already being used in such items as tires, cosmetics, and electronics and will also be utilized increasingly in medical diagnosis, imaging and drug delivery.

A review article on the UCLA research appears in the Feb. 3 issue of the journal Science.

Xradia Receives $1.4 Million Grant for Nano-scale X-ray Microscope

Xradia Receives $1.4 Million Grant for Nano-scale X-ray Microscope

Xradia, Inc., a developer and manufacturer of ultra-high-resolution x-ray imaging systems for 3D tomography and nanotechnology applications, today announced receipt of a $1.4 million grant from the National Institutes of Health (NIH) for the development of an ultra-high-resolution x-ray microscope for the three-dimensional imaging of complex biological systems.

Nanotechnology is emerging as a critical field essential to enabling fundamental breakthroughs in biomedicine and other disciplines. In this respect, single-cell tomography using x-rays has been identified as a major technology need by NIH.

“With unique capabilities in developing ultra-high-resolution x-ray nano-tomography systems, Xradia is in an ideal position to meet this emerging need,” said Dr. Michael Feser, engineering vice president at Xradia.

The company will expand its product line by introducing a new x-ray tomography system designed specifically for biomedical applications. This new product will include capabilities of automated 3D tomographic imaging with single cell or tissue sections at 30nm resolution, and high throughput. A cryogenic sample stage will preserve samples in a frozen-hydrated state, and enable simple preparation without the need for sectioning.

“The new x-ray microscope developed with these funds will bridge the gap between visible light and electron microscopy, and will provide biologists with a powerful and unique vision tool offering new insights on the structure and behavior of cellular organelles,” said Dr. Wenbing Yun, Xradia’s founder and president. “Development of the new microscope is expected to be complete in less than 12 months.”

About Xradia, Inc.

Xradia, Inc. is a privately held company established in 2000 to commercialize high-resolution x-ray microscopes for nondestructive inspection and nano-scale imaging. Initially targeted at failure analysis in the semiconductor IC industry, subsequent developments have led to a suite of commercial x-ray imaging products that have permitted expansion into markets that include metrology in semiconductor IC production, scientific equipment, biomedical research and nanotechnology development. These advanced systems offer outstanding nondestructive imaging capabilities, including nanometer resolution 3D imaging of complex objects, such as IC chips and biological specimens, and element-specific imaging for process control and monitoring in IC manufacturing. The company also supplies advanced x-ray imaging components and state-of-the-art imaging systems to the synchrotron research community. The company is rapidly expanding in response to demand for its unique x-ray imaging products